Sign Out
Syndopa 275 is advocated in the management of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide or manganese intoxication.
Syndopa 275 is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response and with supplemental pyridoxine.
Continue with Google